Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference
26 Abril 2023 - 10:12AM
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage
biotechnology company focused on Alzheimer’s disease, today
announced that Remi Barbier, President & Chief Executive
Officer, has been invited to present at the 2023 H.C. Wainwright
BioConnect Investor Conference in New York. In addition, management
will be available for one-on-one meetings with institutional
investors who are registered to attend this conference.
When: Tuesday, May 2nd at 3pm
Eastern time
Live
Webcast: https://journey.ct.events/view/f51ce8f9-51a5-45e8-891b-e3623ecb6305
Archived Replay:
https://www.CassavaSciences.com/company-presentations
About Cassava Sciences,
Inc.Cassava Sciences is a clinical-stage biotechnology
company based in Austin, Texas. Our mission is to detect and treat
neurodegenerative diseases, such as Alzheimer’s disease. Our novel
science is based on stabilizing—but not removing—a critical protein
in the brain. Our product candidates have not been approved by any
regulatory authority, and their safety, efficacy or other desirable
attributes have not been established. For more information, please
visit: https://www.CassavaSciences.com.
For More Information Contact: Eric Schoen,
Chief Financial Officer(512) 501-2450 or
ESchoen@CassavaSciences.com
Cassava Sciences (NASDAQ:SAVA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Cassava Sciences (NASDAQ:SAVA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024